nuvox_logo 1000 - svg.jpg
  • Pipeline

  • Leadership

  • News

    • Events
  • Publications

    • Acute Hypoxemic Respiratory Failure
    • Hemorrhagic Shock
    • Mechanism Of Action
    • Myocardial Infarction
    • Oncology
    • Pharmacokinetics
    • Stroke
    • Traumatic Brain Injury
  • Careers

  • Contact

  • More

    Use tab to navigate through the menu items.

    Stroke

    Welcoming the New Kid on the Block; A Phase IIb Study of DDFPe in Large Vessel Strokes

    Welcoming the New Kid on the Block; A Phase IIb Study of DDFPe in Large Vessel Strokes

    The design for an efficient Phase IIb clinical trial in stroke to test DDFPe in patients with Large Vessel Occlusions.
    Dodecafluoropentane Emulsion in Acute Ischemic Stroke: A Phase Ib/II Trial

    Dodecafluoropentane Emulsion in Acute Ischemic Stroke: A Phase Ib/II Trial

    This randomized, placebo-controlled, double-blind, dose-escalation clinical trial in acute ischemic stroke patients was designed to...
    NuvOx Pharma’s NanO2 Shows Positive Results in Phase Ib/II Stroke Trial

    NuvOx Pharma’s NanO2 Shows Positive Results in Phase Ib/II Stroke Trial

    Positive results of NuvOx Pharma’s NanO2 (DDFPe) in the treatment of stroke have been published at the International Stroke Conference. A...
    Dodecafluoropentane Improves Neurological Function Following Anterior Ischemic Stroke

    Dodecafluoropentane Improves Neurological Function Following Anterior Ischemic Stroke

    DDFPe reduces infarct volume and neurological function following anterior ischemic stroke.
    DDFPe Extends Window for tPA Therapy in a Rabbit Stroke Model

    DDFPe Extends Window for tPA Therapy in a Rabbit Stroke Model

    DDFPe significantly extends the time window for tPA therapy.
    DDFPe delays and reduces MRI markers of infarction in a rat stroke model

    DDFPe delays and reduces MRI markers of infarction in a rat stroke model

    DDFPe delays and reduces MRI markers of stroke in the early hours following vascular occlusion in a rat stroke model.
    Multiple Applications of DDFPe Prevents Death in a Rabbit Stroke Model

    Multiple Applications of DDFPe Prevents Death in a Rabbit Stroke Model

    Increasing the number of DDFPe applications was significant in reducing the incidence of premature death.
    A preliminary PET evaluation of DDFPe effects on rabbit brain hypoxia in stroke

    A preliminary PET evaluation of DDFPe effects on rabbit brain hypoxia in stroke

    DDFPe alleviates hypoxia in areas of ischemia.
    DDFPe Decreases Stroke Size and Improves Neurological Scores in a Rat Stroke Model

    DDFPe Decreases Stroke Size and Improves Neurological Scores in a Rat Stroke Model

    DDFPe treatment provides significant neuroprotection when assessed six hours post stroke.
    Progress in Dodecafluoropentane Emulsion as a Neuroprotective Agent in a Rabbit Stroke Model

    Progress in Dodecafluoropentane Emulsion as a Neuroprotective Agent in a Rabbit Stroke Model

    Intravenous DDFPe decreases ischemic stroke infarct volumes. Rapid development is warranted.
    Dodecafluoropentane Emulsion Decreases Infarct Volume in a Rabbit Ischemic Stroke Model

    Dodecafluoropentane Emulsion Decreases Infarct Volume in a Rabbit Ischemic Stroke Model

    Intravenous DDFPe in an animal model decreases infarct volumes and protects brain tissue from ischemia justifying further investigation.
    • Pipeline
    • Leadership
    • News
      • Events
    • Publications
      • Acute Hypoxemic Respiratory Failure
      • Hemorrhagic Shock
      • Mechanism Of Action
      • Myocardial Infarction
      • Oncology
      • Pharmacokinetics
      • Stroke
      • Traumatic Brain Injury
    • Careers
    • Contact

    NuvOx Pharma

    1635 E 18th Street

    Tucson, Arizona 85719

    ​

    Privacy Policy

    Terms & Conditions

    Company FCOI

    ​

    © 2020 NuvOx Pharma